You are viewing a preview of...

Repurposing of Reverse Transcriptase Inhibitors to Alleviate TLR5-mediated Inflammation in Cystic Fibrosis

Anti-inflammatory therapy targeting TLR5 to provide therapeutic cystic fibrosis relief, through repurposing reverse transcriptase inhibitors


  • Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CF transmembrane conductance regulator (CTFR) gene
  • This hereditary mutation results in inadequate mucus production and compromises bacterial clearance mechanisms, predisposing CF patients to persistent lung infections
  • To fight bacterial infections, cells express TLR5 in response to bacterial motor protein Flagellum (FLA), which causes an innate immune response
  • Unregulated TLR5 activation in response FLA results in pathogenic inflammation
  • Most notably, P. aeruginosa can cause a life-threatening infection in the pulmonary tract of CF patients by triggering excess TLR5-mediated inflammation
  • Unmet Need: Anti-inflammatory therapy targeting TLR5 to provide therapeutic relief that does not drive immunotoxicity

Log in or create a free account to continue reading